Efficacy of roflumilast foam in psoriasis
Roflumilast foam, 0.3%, significantly improved scalp and body psoriasis and reduced itch within weeks, with low adverse event rates. It offers an effective, well-tolerated topical monotherapy option for patients aged 12 and older.









